Lilly to help BioAge test muscle regeneration therapy in combo with weight loss drug tirzepatide

BioAge Labs has garnered the support of Eli Lilly to run a trial combining a muscle regeneration therapy with the Big Pharma’s tirzepatide for healthier weight loss.

While no financial details were disclosed, BioAge will conduct a phase 2 trial of its oral apelin receptor agonist BGE-105 (azelaprag) along with Lilly’s GLP-1/GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro. The main goal of the trial, which is expected to get underway in mid-2024, will be total weight loss with other goals examining additional potential benefits of the mechanism.